Another ten stories in antiviral drug discovery (part C): "Old" and "new" antivirals, strategies, and perspectives.
The ten stories told here deal with (i) ribavirin as an inhibitor of IMP dehydrogenase and (ii) ribavirin, in combination with pegylated interferon, as the present "standard of care" for hepatitis C; (iii) S-adenosylhomocysteine hydrolase inhibitors as antiviral agents; (iv) new adamantadine derivatives for the treatment of influenza A virus infections; (v) 5-substituted 2'-deoxyuridines (i.e. IDU, TFT) for the treatment of herpes simplex virus (HSV) infections; (vi) acyclic guanosine analogues (e.g. acyclovir) for the treatment of HSV infections; (vii) OMP decarboxylase inhibitors (i.e. pyrazofurin) and CTP synthetase inhibitors (i.e. cyclopentenylcytosine) as possible antiviral agents; (viii) the future of cidofovir (and alkoxyalkyl esters thereof) and ST-246 as potential antipoxvirus agents; (ix) the two decade journey from tivirapine to rilpivirine in the ultimate therapy of HIV infections; and (x) the extension of the therapeutic application of tenofovir disoproxil fumarate (Viread) to the treatment of hepatitis B virus infection, in addition to HIV infection.
De Clercq
Erik
E
Rega Institute for Medical Research, K.U.Leuven, Minderbroedersstraat 10, B-3000 Leuven, Belgium. erik.declercq@rega.kuleuven.be
D000998:Antiviral Agents / Q000627:therapeutic use*; D055808:Drug Discovery / Q000639:trends*; D017320:HIV Protease Inhibitors / Q000627:therapeutic use; D019698:Hepatitis C, Chronic / Q000188:drug therapy / Q000821:virology; D007168:IMP Dehydrogenase / Q000037:antagonists & inhibitors; D012254:Ribavirin / Q000627:therapeutic use*
D000998:Antiviral Agents; D017320:HIV Protease Inhibitors; D012254:Ribavirin; D007168:IMP Dehydrogenase